Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) improved survival in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Patient-reported symptoms in this context were poorly studied. The study aimed to compare symptom severity between patients and clinicians.

Methodology

The secondary analysis of the AMI clinical trial comparing changes in the gut microbiota in patients with la/mUC treated with pembrolizumab was conducted in nine French centers. Secondary endpoints were expected in this prospective study. Patient-Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) and CTCAE were assessed respectively by patients and clinicians before pembrolizumab initiation, and at each treatment visit until treatment cycle 12. Agreement in se

SUBMITTER: Annakib S 

PROVIDER: S-EPMC12010202 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature